Our Science
Our Science
Cutting-edge research and technology
Our initiatives
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change
pmi-emblem

Why Invest in PMI?

We've built the worlds most succesful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 8788

0.50 (0.57%)

Investor Relations

Latest Press Releases

Media Center
  • Press Release 19 Feb, 2020

    Even If Vital Strategies Won’t Talk with Us, Philip Morris International Wants to Talk About a Smoke-Free Future

  • Press Release 19 Feb, 2020

    Philip Morris International Inc. Presents at the CAGNY Conference;

  • News 19 Feb, 2020

    Who's afraid of a scientist?

  • Press Release 18 Feb, 2020

    Philip Morris International Inc. Presents at Chief Executives For Corporate Purpose (CECP) 2020 CEO Investor Forum

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.